arrow_back Back Filing freshness 20-F FY 2025 SEC EDGAR

download Export Data

NeuroSense Therapeutics Ltd.

NRSN

$0.50 ▼ -0.02 (-3.24%) at close

7 Visible periods

18 Metrics

Absolute Benchmarks

Price Chart

Health

Poor

Neutral Absolute basis

auto_awesome

Analytical Summary

On an absolute basis, NeuroSense Therapeutics Ltd. shows solid but mixed fundamentals, with Return on Invested Capital holding up well. Watch FCF / Net Income against typical quality thresholds. These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.

Market Cap $12.7M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC 561.4% ↗

FCF / Share $-0.30 ↗

Trailing P/E —

Price / Book —

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

7-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-11.12M

↓ -9.0% —

FCF / Share Free cash flow per share

$-0.30

↑ +44.7% —

info Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.

trending_up

Bullish Indicators

Return on Invested CapitalReturn on Invested Capital of 561.4% is excellent on an absolute basis (target > 10%)

warning

Bearish Risks

FCF / Net IncomeFCF / Net Income of 0.69x is weak on an absolute basis (target > 1x)

Health Breakdown

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗	FY 2021 Dec 31, 2021 20-F ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2019 20-F ↗
EPS Growth YoY (%)	18.5% Good ↓ Good Declining Year-over-year change in earnings per share Optimal: > 10%	27.0% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	18.7% Good Good Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—
Net Income Growth YoY (%)	-9.0% Weak ↑ Weak Improving Year-over-year change in net income	-1.0% Weak ↑ Weak Improving Year-over-year change in net income	3.7% Caution ↑ Caution Improving Year-over-year change in net income	-159.6% Weak ↓ Weak Declining Year-over-year change in net income	-42.9% Weak Weak Year-over-year change in net income	-131.4% Weak Weak Year-over-year change in net income	—
FCF Growth YoY (%)	44.7% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	11.3% Fair Fair Year-over-year change in free cash flow	8.0% Fair Fair Year-over-year change in free cash flow	—	—	—	—

💰 Are margins durable? 1 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗	FY 2021 Dec 31, 2021 20-F ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2019 20-F ↗
FCF / Net Income (x)	0.69x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.99x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.83x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.73x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗	FY 2021 Dec 31, 2021 20-F ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2019 20-F ↗
Return on Invested Capital (%)	561.4% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	-302.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	541.1% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	-142.7% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—	—	—
Return on Capital (%) (%)	-1078.3% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-216.4% Weak Weak Operating profit relative to total assets Optimal: > 10%	-378.3% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—	—
Return on Common Equity (%) (%)	—	—	—	-179.5% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1297%)	—	—	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗	FY 2021 Dec 31, 2021 20-F ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2019 20-F ↗
Net Debt (USD)	$-166.00K	$-3.38M	$-2.64M	—	—	—	—

📊 What does each share earn? 5 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗	FY 2021 Dec 31, 2021 20-F ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2019 20-F ↗
Basic EPS, GAAP (USD)	$-0.44	$-0.54	$-0.74	$-0.91	—	—	—
Free Cash Flow per Share (USD)	$-0.30	$-0.54	$-0.61	$-0.67	—	—	—
Book Value per Share (USD)	$-0.05	$0.11	$-0.11	$0.51	—	—	—
Tangible Book Value per Share (USD)	$-0.05	$0.11	$-0.11	$0.51	—	—	—
Basic Weighted Avg Shares (shares)	25.48M	18.60M	13.64M	11.50M	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗	FY 2021 Dec 31, 2021 20-F ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2019 20-F ↗
Working Capital (USD)	$-1.74M	$2.41M	$-543.00K	—	—	—	—
Total Equity (USD)	$-1.56M	$2.58M	$-1.76M	$5.84M	—	—	—

📋 What is driving earnings? 3 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗	FY 2021 Dec 31, 2021 20-F ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2019 20-F ↗
Depreciation Expense (USD)	$16.00K	$22.00K	$21.00K	$12.00K	—	—	—
Net Income, GAAP (USD)	$-11.12M	$-10.21M	$-10.11M	$-10.49M	$-4.04M	$-2.83M	$-1.22M
Operating Cash Flow (USD)	$-7.67M	$-10.13M	$-8.35M	$-7.62M	—	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 6 quarters

NeuroSense Therapeutics Ltd.

Analytical Summary

7-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Benchmarks unavailable

Compare NRSN with peers